Highly Efficient Perfusion Processes Using XCell® ATF 2 and ATF 6 Single-Use Devices for 50 Days

BPI Contributor

April 18, 2024

30 Min View
Repligen XCell® Large Scale System
Repligen Corporation

Date: Apr 18, 2024

Duration: 30 Min

This webcast features: Jan Ott, Research Associate,ZHAW Life Sciences and Facility Management.

The current focus in industry and research is on the process intensification of biopharmaceutical production processes. In the upstream process, one promising approach is to switch from fed-batch to perfusion mode, which promises higher productivity. In this collaboration project, an XCell® ATF 6 Single-Use Device operated with the XCell® LS Controller was combined with the Thermo Scientific 50 L HyPerforma™ DynaDrive™ Single-Use Bioreactor.

To demonstrate the scalability, the process was also carried out in a 2 L glass bioreactor with an XCell® ATF 2 Single-Use Device. Both cultivations were fully automated regarding bleed, harvest, and glucose control.

In summary, the results presented show how highly productive production processes are possible with modern cell retention methods and innovative bioreactors. The scale transfer from laboratory to pilot scale was carried out successfully and comparable results in product quality were achieved at both scales.

Key Takeaways:

  • A highly efficient perfusion process was enabled with XCell® ATF 2 and XCell® ATF 6 devices.

  • The XCell® ATF Devices performed well over the entire cultivation period of 50 days.

  • More than 1 g/L mAb was harvested during the production phase.

Just fill out the form below to watch the recorded webcast now.

You May Also Like